PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Soares MO, Welton NJ, Harrison DA, et al. An Evaluation of the Feasibility, Cost and Value of Information of a Multicentre Randomised Controlled Trial of Intravenous Immunoglobulin for Sepsis (Severe Sepsis and Septic Shock): Incorporating a Systematic Review, Meta-Analysis and Value of Information Analysis. Southampton (UK): NIHR Journals Library; 2012 Feb. (Health Technology Assessment, No. 16.7.)

References

1.
Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/ SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101:1644–55. [PubMed: 1303622]
2.
Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003;31:1250–6. [PubMed: 12682500]
3.
Harrison DA, Welch CA, Eddleston JM. The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: secondary analysis of a high quality clinical database, the ICNARC Case Mix Programme Database. Crit Care. 2006;10:R42. [PMC free article: PMC1550902] [PubMed: 16542492]
4.
Linde-Zwirble WT, Angus DC. Severe sepsis epidemiology: sampling, selection, and society. Crit Care. 2004;8:222–6. [PMC free article: PMC522859] [PubMed: 15312201]
5.
Padkin A, Goldfrad C, Brady AR, Young D, Black N, Rowan K. Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland. Crit Care Med. 2003;31:2332–8. [PubMed: 14501964]
6.
Jolles S, Sewell WAC, Misbah SA. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol. 2005;142:1–11. [PMC free article: PMC1809480] [PubMed: 16178850]
7.
Sewell WA, Jolles S. Immunomodulatory action of intravenous immunoglobulin. Immunology. 2002;107:387–93. [PMC free article: PMC1782817] [PubMed: 12460182]
8.
Wallington T. New uses for IVIgG immunoglobulin therapies. Vox Sang. 2004;87:155–7. [PubMed: 15209904]
9.
Alejandria MM, Lansang MA, Dans LF, Mantaring JB. Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst Rev. 2002;1:CD001090. [PubMed: 11869591]
10.
Kreymann KG, de Heer G, Nierhaus A, Kluge S. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med. 2007;35:2677–85. [PubMed: 18074464]
11.
Laupland KB, Kirkpatrick AW, Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Crit Care Med. 2007;35:2686–92. [PubMed: 18074465]
12.
Turgeon AF, Hutton B, Fergusson DA, McIntyre L, Tinmouth AA, Cameron DW, et al. Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Ann Intern Med. 2007;146:193–203. [PubMed: 17283351]
13.
Norrby-Teglund A, Haque KN, Hammarstrom L. Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis. J Intern Med. 2006;260:509–16. [PubMed: 17116001]
14.
Pildal J, Gøtzsche PC. Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review. Clin Infect Dis. 2004;39:38–46. [PubMed: 15206051]
15.
Alejandria MM, Lansang MA, Dans LF, Mantaring JB. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock (review) Cochrane Library. 2010;(2) [PubMed: 24043371]
16.
Department of Health. Demand Management Plan for Immunoglobulin Use. 2nd edn. London: Department of Health; 2008.
17.
Department of Health. Clinical Guidelines for Immunoglobulin Use. 2nd edn. London: Department of Health; 2008.
18.
Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008;36:296–327. [PubMed: 18158437]
19.
Levy MM, Pronovost PJ, Dellinger RP, Townsend S, Resar RK, Clemmer TP, et al. Sepsis change bundles: converting guidelines into meaningful change in behavior and clinical outcome. Crit Care Med. 2004;32:S595–7. [PubMed: 15542969]
20.
Surving Sepsis Campain. Severe sepsis bundles. [18 August 2010]. URL: www​.survivingsepsis.com/node/89.
21.
Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004;32:858–73. [PubMed: 15090974]
22.
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–6. [PMC free article: PMC2335261] [PubMed: 18436948]
23.
Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360:1283–97. [PubMed: 19318384]
24.
Survive sepsis. [18 August 2010]. URL: www​.survivesepsis.org.uk.
25.
Jadad AR, Moore A, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized trials: is blinding necessary? Control Clin Trials. 1996;17:12. [PubMed: 8721797]
26.
Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818–29. [PubMed: 3928249]
27.
Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA. 1993;270:2957–63. [PubMed: 8254858]
28.
Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707–10. [PubMed: 8844239]
29.
Elebute EA, Stoner HB. The grading of sepsis. Br J Surg. 1983;70:29–31. [PubMed: 6824878]
30.
Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34. [PMC free article: PMC2127453] [PubMed: 9310563]
31.
Higgins JPT, Whitehead A. Borrowing strength from external trials in a meta-analysis. Stat Med. 1996;15:2733–49. [PubMed: 8981683]
32.
Caldwell DM, Ades AE, Higgins JPT. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005;331:897–900. [PMC free article: PMC1255806] [PubMed: 16223826]
33.
Ades AE, Sculpher M, Sutton A, Abrams K, Copper N, Welton NJ, et al. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics, PharmacoEcon. 2006;24:1–19. [PubMed: 16445299]
34.
Ades A, Welton N, Lu G. Introduction to mixed treatment comparisons. 2005. [17 October 2011]. URL: www​.bris.ac.uk/cobm/research/mpes/mtc​.html.
35.
Lunn D, Spiegelhalter D, Thomas A, Best N. The BUGS project: evolution, critique and future directions. Stat Med. 2009;28:3049–67. [PubMed: 19630097]
36.
Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS – a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput. 2000;10:325–37.
37.
Spiegelhalter DJ, Best NG, Carlin BP, van der Linde A. Bayesian measures of model complexity and fit. J R Stat Soc Ser B. 2002;64:583–616.
38.
Vogel F, Exner M, Franke P, Gien C. Nosokomiale sepsis. In: Deicher H, Schoppe W, editors. Klinisch angewandte immunologie-sepsis therapie mit IgM-angereichertem immunoglobulin. Berlin: Springer-Verlag; 1988. pp. 30–41.
39.
Dominioni L, Dionigi R, Zanello M, Chiaranda M, Dionigi R, Acquarolo A, et al. Effects of high-dose IgG on survival of surgical patients with sepsis scored of 20 or greater. Arch Surg. 1991;126:236–40. [PubMed: 1992998]
40.
Just HM, Metzger M, Vogel W, Penack O. Einfluss einer adjuvanten immunglobulintherapie auf infektionen bei patienten einer operativen intensiv-therapie-station. Klin Wochenschr. 1986;64:245–56. [PubMed: 3713101]
41.
Jesdinsky HJ, Tempel G, Castrup HJ, Seifert J. Cooperative group of additional immuinoglobulin therapy in severe bacterial infections: results of a multicenter randomized controlled trial in cases of diffuse fibrinpurulent peritonitis. Klin Wochenschr. 1987;65:1132–8. [PubMed: 3323648]
42.
Rodriguez A, Rello J, Neira J, Maskin B, Ceraso D, Vasta L, et al. Effects of high-dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery. Shock. 2005;23:298–304. [PubMed: 15803051]
43.
Hentrich M, Fehnle K, Ostermann H, Kienast J, Cornely O, Salat C, et al. IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple-center trial. Crit Care Med. 2006;34:1319–25. [PubMed: 16540956]
44.
Karatzas S, Boutzouka E, Venetsanou K, Myrianthefs P, Fildisis G, Baltopoulos G. The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis: another point of view. Crit Care. 2002;6:543–4. [PMC free article: PMC153443] [PubMed: 12512504]
45.
Tugrul S, Ozcan PE, Akinci O, Seyhun Y, Cagatay A, Cakar N, et al. The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis. Crit Care. 2002;6:357–62. [PMC free article: PMC125317] [PubMed: 12225613]
46.
Behre G, Ostermann H, Schedel I, Helmerking M, Schiel X, Rothenburger M, et al. Endotoxin concentrations and therapy with polyclonal IgM-enriched immunoglobulins in neutropenic cancer patients with sepsis syndrome: pilot study and interim analysis of a randomized trial. Anti Infect Drugs Chemother. 1995;13:129–34.
47.
Schedel I, Dreikhausen U, Nentwig B, Hockenschnieder M, Rauthmann D, Balikcioglu S, et al. Treatment of Gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial. Crit Care Med. 1991;19:1104–13. [PubMed: 1884609]
48.
Wesoly C, Kipping N, Grundmann R. Immunglobulintherapie der postoperativen sepsis. Z Exp Chir Transplant Kunstliche Organe. 1990;23:213–16. [PubMed: 2095647]
49.
Spannbrucker N, Munch HG, Kunze R, Vogel F. Auswirkungen von immunglobulinsubstitution bei sepsis. Intensivmedizin. 1987;6:314.
50.
Dominioni L, Bianchi V, Imperatori A, Minoia G, Dionigi R, Abakumov MM. High-dose intravenous IgG for treatment of severe surgical infections. Dig Surg. 1996;13:430–4.
51.
Burns ER, Lee V, Rubinstein A. Treatment of septic thrombocytopenia with immune globulin. J Clin Immunol. 1991;11:363–8. [PubMed: 1761642]
52.
De Simone C, Delogu G, Corbetta G. Intravenous immunoglobulins in association with antibiotics: a therapeutic trial in septic intensive care unit patients. Crit Care Med. 1988;16:23–6. [PubMed: 3276446]
53.
Werdan K, Pilz G, Bujdoso O, Fraunberger P, Neeser G, Schmieder RE, et al. Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit Care Med. 2007;35:2693–701. [PubMed: 18074471]
54.
Grundmann R, Hornung M. Immunoglobulin therapy in patients with endotoxemia and postoperative sepsis – a prospective randomized study. Prog Clin Biol Res. 1988;272:339–49. [PubMed: 3293080]
55.
Yakut M, Cetiner S, Akin A, Tan A, Kaymakcioglu N, Simsek A, et al. Sepsisdeki hastalarda immunglobulin G (IgG) kullaniminin mortalite oranina etkisi. GATA Bulteni. 1998;40:76–81.
56.
Darenberg J, Ihendyane N, Sjolin J, Aufwerber E, Haidl S, Follin P, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2003;37:333–40. [PubMed: 12884156]
57.
Lindquist L, Lundbergh P, Maasing R. Pepsin-treated human gamma globulin in bacterial infections: a randomized study in patients with septicaemia and pneumonia. Vox Sang. 1981;40:329–37. [PubMed: 6166128]
58.
Masaoka T, Hasegawa H, Takaku F. The efficacy of intravenous immunoglobulin in combination therapy with antibiotics for severe infections. Jpn J Chemother. 2000;48:199–217.
59.
Raphael JC, Chevret S, Harboun M, Jars-Guincestre MC., French Guillain–Barré Syndrome Cooperative G. Intravenous immune globulins in patients with Guillain–Barré syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatry. 2001;71:235–8. [PMC free article: PMC1737513] [PubMed: 11459901]
60.
Tugrul S, Ozcan PE, Akinci O, Cagatay A, Cakar N, Esen F. [[The effect of pentaglobin therapy on prognosis in patients with severe sepsis]]. Ulus Travma Derg. 2001;7:219–23. [PubMed: 11705075]
61.
Bellomo R, Uchino S, Naka T, Wan L. Hidden evidence to the West: multicentre, randomised, controlled trials in sepsis and systemic inflammatory response syndrome in Japanese journals. Intensive Care Med. 2004;30:911–17. [PubMed: 15052382]
62.
Reith HB, Rauchschwalbe SK, Mittelkotter U, Engemann R, Thiede A, Arnold A, et al. IgM-enriched immunoglobulin (pentaglobin) positively influences the course of post-surgical intra-abdominal infections. Eur J Med Res. 2004;9:479–84. [PubMed: 15546815]
63.
Buda S, Riefolo A, Biscione R, Goretti E, Cattabriga I, Grillone G, et al. Clinical experience with polyclonal IgM-enriched immunoglobulins in a group of patients affected by sepsis after cardiac surgery. J Cardiothorac Vasc Anesth. 2005;19:440–5. [PubMed: 16085247]
64.
Khan S, Sewell WAC. Risks of intravenous immunoglobulin in sepsis affect trial design. Ann Intern Med. 2007;147:813. [PubMed: 18056670]
65.
Calandra T, Glauser MP, Schellekens J, Verhoef J., Swiss-Dutch J5 Immunoglobulin Study Group. Treatment of Gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind randomized trial. J Infect Dis. 1988;158:312–19. [PubMed: 3136210]
66.
Pilz G, Appel R, Kreuzer E, Werdan K. Comparison of early IgM-enriched immunoglobulin vs polyvalent IgG administration in score-identified postcardiac surgical patients at high risk of sepsis. Chest. 1997;111:419–26. [PubMed: 9041991]
67.
Keane W, Hirata-Dulas CAI, Bullock ML, Ney AL, Guay DRP, Kalil RSN, et al. Adjunctive therapy with intravenous human immunoglobulin G improved survival of patients with acute renal failure. J Am Soc Nephrol. 1991;2:841–7. [PubMed: 1751787]
68.
Vincent JL, Navickis RJ, Wilkes MM. Morbidity in hospitalized patients receiving human albumin: a meta-analysis of randomized, controlled trials. Crit Care Med. 2004;32:2029–38. [PubMed: 15483411]
69.
Moreno SG, Sutton AJ, Ades AE, Stanley TD, Abrams KR, Peters JL, et al. Assessment of regression-based methods to adjust for publication bias through a comprehensive simulation study. BMC Med Res Methodol. 2009;9:2. [PMC free article: PMC2649158] [PubMed: 19138428]
70.
Moreno SG, Sutton AJ, Turner EH, Abrams KR, Cooper NJ, Palmer TM, et al. Novel methods to deal with publication biases: secondary analysis of antidepressant trials in the FDA trial registry database and related journal publications. BMJ. 2009;339:b2981. [PMC free article: PMC2723217] [PubMed: 19666685]
71.
Werdan K. Mirror, mirror on the wall, which is the fairest meta-analysis of all? Crit Care Med. 2007;35:2852–4. [PubMed: 18043202]
72.
Drummond MF. Methods for the economic evaluation of health care programmes. 3rd edn. Oxford: Oxford University Press; 2005.
73.
Neilson AR, Burchardi H, Schneider H. Cost-effectiveness of immunoglobulin M-enriched immunoglobulin (Pentaglobin) in the treatment of severe sepsis and septic shock. J Crit Care. 2005;20:239–49. [PubMed: 16253792]
74.
Manns BJ, Lee H, Doig CJ, Johnson D, Donaldson C. An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med. 2002;347:993–1000. [PubMed: 12324556]
75.
Angus DC, Linde-Zwirble WT, Clermont G, Ball DE, Basson BR, Ely EW, et al. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med. 2003;31:1–11. [PubMed: 12544986]
76.
Betancourt M, McKinnon PS, Massanari RM, Kanji S, Bach D, Devlin JW. An evaluation of the cost effectiveness of drotrecogin alfa (Activated) relative to the number of organ system failures. PharmacoEconomics. 2003;21:1331–40. [PubMed: 14750900]
77.
Fowler RA, Hill-Popper M, Stasinos J, Petrou C, Sanders GD, Garber AM. Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis. J Crit Care. 2003;18:181–91. [PubMed: 14595571]
78.
Neilson AR, Burchardi H, Chinn C, Clouth J, Schneider H, Angus D. Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany. J Crit Care. 2003;18:217–27. [PubMed: 14691895]
79.
Sacristán JA, Prieto L, Huete T, Artigas A, Badia X, Chinn C, et al. [Cost-effectiveness of drotrecogin alpha [activated] in the treatment of severe sepsis in Spain]. Gac Sanit. 2004;18:50–7. [PubMed: 14980173]
80.
Davies A, Ridley S, Hutton J, Chinn C, Barber B, Angus DC. Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom. Anaesthesia. 2005;60:155–62. [PubMed: 15644013]
81.
Hjelmgren J, Persson U, Tennvall GR. Local treatment pattern versus trial-based data: a cost-effectiveness analysis of drotrecogin alfa (activated) in the treatment of severe sepsis in Sweden. Am J Ther. 2005;12:425–30. [PubMed: 16148428]
82.
Green C, Dinnes J, Takeda A, Shepherd J, Hartwell D, Cave C, et al. Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation. Health Technol Assess. 2005;>9(11) [PubMed: 15774234]
83.
Green C, Dinnes J, Takeda AL, Cuthbertson BH. Evaluation of the cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom. Int J Technol Assess Health Care. 2006;22:90–100. [PubMed: 16673685]
84.
Franca LR, Launois R, Le Lay K, Aegerter P, Bouhassira M, Meshaka P, et al. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis with multiple organ failure. Int J Technol Assess Health Care. 2006;22:101–8. [PubMed: 16673686]
85.
Dhainaut JF, Payet S, Vallet B, Franca L, Annane D, Bollaert PE, et al. Cost-effectiveness of activated protein C in real-life clinical practice. Crit Care. 2007;11:R99. [PMC free article: PMC2556742] [PubMed: 17822547]
86.
Costa V, Brophy JM. Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis. BMC Anaesthesiol. 2007;7:5. [PMC free article: PMC1929064] [PubMed: 17592639]
87.
Guidet B, Mosqueda GJ, Priol G, Aegerter P. The COASST study: cost-effectiveness of albumin in severe sepsis and septic shock. J Crit Care. 2007;22:197–203. [PubMed: 17869969]
88.
Huang DT, Clermont G, Dremsizov TT, Angus DC. Implementation of early goal-directed therapy for severe sepsis and septic shock: a decision analysis. Crit Care Med. 2007;35:2090–100. [PubMed: 17855823]
89.
Talmor D, Greenberg D, Howell MD, Lisbon A, Novack V, Shapiro N. The costs and cost-effectiveness of an integrated sepsis treatment protocol. Crit Care Med. 2008;36:1168–74. [PubMed: 18379243]
90.
Alejandria MM, Lansang MA, Dans LF, Mantaring JB. Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst Rev. 2001;2:CD001090. [PubMed: 11405973]
91.
Briggs A, Claxton K, Sculpher MJ. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.
92.
Bernard GR, Vincent JL, Laterre P, Larosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699–709. [PubMed: 11236773]
93.
Quartin AA, Schein RMH, Kett DH, Peduzzi PN. Magnitude and duration of the effect of sepsis on survival. JAMA. 1997;277:1058–63. [PubMed: 9091694]
94.
Wright JC, Plenderleith L, Ridley SA. Long-term survival following intensive care: subgroup analysis and comparison with the general population. Anaesthesia. 2003;58:637–42. [PubMed: 12790812]
95.
Angus DC, Laterre PF, Helterbrand J, Ely EW, Ball DE, Garg R, et al. The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis. Crit Care Med. 2004;32:2199–206. [PMC free article: PMC4714718] [PubMed: 15640631]
96.
Drabinski A, Williams G, Formica C. Observational evaluation of health state utilities. Value Health. 2001;4:130.
97.
Angus DC, Musthafa AA, Clermont G, Griffin MF, Linde-Zwirble WT, Dremsizov TT, et al. Quality-adjusted survival in the first year after the acute respiratory distress syndrome. Am J Respir Crit Care Med. 2001;163:1389–94. [PubMed: 11371406]
98.
[18 August 2010]. URL: www​.icapp.nhs.uk/docdat/
99.
Harrison DA, Brady AR, Rowan K. Case mix, outcome and length of stay for admissions to adult, general critical-care units in England, Wales and Northern Ireland: the Intensive Care National Audit & Research Centre Case Mix Programme Database. Crit Care. 2004;8:R99–111. [PMC free article: PMC420043] [PubMed: 15025784]
100.
Harrison DA, Parry GJ, Carpenter JR, Short A, Rowan K. A new risk prediction model for critical care: the Intensive Care National Audit & Research Centre (ICNARC) model. Crit Care Med. 2007;35:1091–8. [PubMed: 17334248]
101.
Williams TA, Dobb GJ, Finn JC, Webb SAR. Long-term survival from intensive care: a review. Intensive Care Med. 2005;31:1306–15. [PubMed: 16132895]
102.
Ghelani D, Moran JL, Sloggett A, Leeson RJ, Peake SL. Long-term survival of intensive care and hospital patient cohorts compared with the general Australian population: a relative survival approach. J Eval Clin Pract. 2009;15:425–35. [PubMed: 19366395]
103.
Karlsson S, Varpula M, Ruokonen E, Pettila V, Parviainen I, Ala-Kokko TI, et al. Incidence, treatment, and outcome of severe sepsis in ICU-treated adults in Finland: the Finnsepsis study. Intensive Care Med. 2007;33:435–43. [PubMed: 17225161]
104.
Varpula M, Karlsson S, Parviainen I, Ruokonen E. Community-acquired septic shock: early management and outcome in a nationwide study in Finland. Acta Anaesthesiol Scand. 2007;51:1320–6. [PubMed: 17944634]
105.
Weycker D, Akhras KS, Edelsberg J, Angus DC, Oster G. Long-term mortality and medical care charges in patients with severe sepsis. Crit Care Med. 2003;31:2316–23. [PubMed: 14501962]
106.
Leibovici L, Samra Z, Konigsberger H, Drucker M, Ashkenazi S, Pitlik SD. Long-term survival following bacteremia or fungemia. JAMA. 1995;274:807–12. [PubMed: 7650804]
107.
Perl TM, Dvorak LA, Hwang T, Wenzel RP. Long-term survival and function after suspected Gram-negative sepsis. JAMA. 1995;274:338–45. [PubMed: 7609265]
108.
Sasse KC, Nauenberg E, Long A, Anton B, Tucker HJ, Hu TW. Long-term survival after intensive-care unit admission with sepsis. Crit Care Med. 1995;23:1040–7. [PubMed: 7774214]
109.
Karlsson S, Ruokonen E, Varpula T, Ala-Kokko TI, Pettila V. Long-term outcome and quality-adjusted life years after severe sepsis. Crit Care Med. 2009;37:1268–74. [PubMed: 19242321]
110.
Granja C, Dias C, Costa-Pereira A, Sarmento A. Quality of life of survivors from severe sepsis and septic shock may be similar to that of others who survive critical illness. Critical Care. 2004;8:R91–8. [PMC free article: PMC420036] [PubMed: 15025783]
111.
Korošec Jagodic H, Jagodic K, Podbregar M. Long-term outcome and quality of life of patients treated in surgical intensive care: a comparison between sepsis and trauma. Crit Care. 2006;10:R134. [PMC free article: PMC1751058] [PubMed: 16978417]
112.
Williams A. Euroqol - a new facility for the measurement of health-related quality-of-life. Health Policy. 1990;16:199–208. [PubMed: 10109801]
113.
National Institute for Health and Clinical Excellence. Guidance to the methods of technology appraisal. London: National Institute for Health and Clinical Excellence; 2008.
114.
R Development Core Team. The R project for statistical computing. 2010. [17 October 2011]. URL: www​.R-project.org.
115.
Briggs AH, Goeree R, Blackhouse G, O'Brien BJ. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making. 2002;22:290–308. [PubMed: 12150595]
116.
Claxton K, Ginnelly L, Sculpher M, Philips Z, Palmer S. A pilot study on the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment programme. Health Technol Assess. 2004;8(31) [PubMed: 15248937]
117.
Ades AE, Lu G, Claxton K. Expected value of sample information calculations in medical decision modeling. Med Decis Making. 2004;24:207–27. [PubMed: 15090106]
118.
Claxton K, Posnett J. An economic approach to clinical trial design and research priority-setting. Health Econ. 1996;5:513–24. [PubMed: 9003938]
119.
Cuthbertson BH, Roughton S, Jenkinson D, Maclennan G, Vale L. Quality of life in the five years after intensive care: a cohort study. Crit Care. 2010;14:R6. [PMC free article: PMC2875518] [PubMed: 20089197]
120.
British Medical Association amd Royal Pharmaceutical Society of Great Britain. British national formulary. No. 58. London: BMA and RPS; Sep, 2009. 2009.
121.
Department of Health. NHS reference costs 2007/08. [17 October 2011]. URL: www​.dh.gov.uk/en/Publicationsandstatistics​/Publications/PublicationsPolicyAndGuidance/DH_098945.
122.
Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 2001;10:779–87. [PubMed: 11747057]
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

Cover of An Evaluation of the Feasibility, Cost and Value of Information of a Multicentre Randomised Controlled Trial of Intravenous Immunoglobulin for Sepsis (Severe Sepsis and Septic Shock): Incorporating a Systematic Review, Meta-Analysis and Value of Information Analysis
An Evaluation of the Feasibility, Cost and Value of Information of a Multicentre Randomised Controlled Trial of Intravenous Immunoglobulin for Sepsis (Severe Sepsis and Septic Shock): Incorporating a Systematic Review, Meta-Analysis and Value of Information Analysis.
Health Technology Assessment, No. 16.7.
Soares MO, Welton NJ, Harrison DA, et al.
Southampton (UK): NIHR Journals Library; 2012 Feb.

Download

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...